Regulatory News
October 5, 2017 / 4:50 PM / a year ago

BRIEF-U.S. Appellate Court rules Sanofi, Regeneron can continue manufacturing PRALUENT in U.S.

1 Min Read

Oct 5 (Reuters) - Sanofi SA:

* Appellate Court orders a new trial and vacates permanent injunction in ongoing patent case regarding Praluent® (alirocumab)

* ‍Sanofi - co and Regeneron do not anticipate any new trial proceedings to start in 2017

* Sanofi says U.S. Court of Appeals ruling means that co, Regeneron will continue marketing, selling, manufacturing Praluent (alirocumab) injection in U.S

* ‍Sanofi - Court has ordered new trial, vacated permanent injunction in dispute concerning Amgen’s asserted patent claims for antibodies targeting PCSK9​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below